CD155 and CD112 as possible therapeutic targets of <i>FLT3</i> inhibitors for acute myeloid leukemia.

导出 OA

翻译打印收藏纠错

作者： Yuta,Kaito ^[1] ; Mitsuhito,Hirano ^[2] ; Muneyoshi,Futami ^[2] ; Masanori,Nojima ^[3] ; Hideto,Tamura ^[4] ; Arinobu,Tojo ^[1] ; Yoichi,Imai ^[2]

作者单位： Department of Hematology/Oncology, Research Hospital, The Institute of Medical Science, The University of Tokyo, Tokyo 108-8639, Japan. ^[1] Department of Molecular Therapy, Advanced Clinical Research Center, The University of Tokyo, Tokyo 108-8639, Japan. ^[2] Department of Translational Research, The Institute of Medical Science, The University of Tokyo, Tokyo 108-8639, Japan. ^[3] Department of Hematology, Saitama Medical Center, Dokkyo Medical University, Saitama 343-8555, Japan. ^[4]

关键词 CD112 CD155 FMS-like tyrosine kinase 3 inhibitor acute myeloid leukemia immune checkpoint natural killer cell

DOI 10.3892/ol.2021.13169

PMID 34992684

发布时间 2022-01-08

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交